If we have selected the wrong experience for you, please change it above.
Why does cross-border M&A fail at the board level? In the fourth and final part of our cross-border M&A series, we detail why it’s rarely a lack of diligence, but a mismatch in focus. Learn how to transform boards from episodic approvers into strategic partners.
Boards are deeply involved in cross-border M&A, yet many deals still underperform.
This is not because boards are disengaged. Our survey of M&A executives involved in cross-border transactions suggests that most boards are perceived as effective or very effective. The issue is where and how boards apply their attention across the deal life cycle.
Boards tend to concentrate oversight at visible milestones: signing, closing, and formal approvals. But those moments are rarely the ones where value is created or destroyed. Risk takes shape earlier, through strategy, diligence, and operating model definition. Value is realized—or lost—later, through sustained post-merger integration.
Cross-border M&A often breaks down above the deal team, when board oversight is misaligned with the ways deals actually create value.
Three interdependent factors anchor effective cross-border deals (figure 1):
Boards are typically most active at approving transactions, yet least engaged where these three factors are defined, challenged, and stress-tested.
Figure 1: Board attention vs. value creation across the cross-border M&A life cycle
Boards tend to concentrate oversight at visible deal milestones such as signing and closing. However, survey insights and deal experience show that value is shaped earlier—through strategy, diligence, and operating model definition—and realized later through sustained post-merger integration.
Our survey respondents describe a clear gap between the ways boards typically involve themselves in M&A deals and the ways board involvement could better support cross-border M&A outcomes.
While Japanese and non-Japanese executives emphasize different friction points, there is still a common theme: Boards should act less as episodic approvers and more as continuous strategic partners.
For M&A leaders, the challenge is not to redesign board structures unilaterally, but to engage boards differently across the deal life cycle—in ways that align oversight with the steps that actually shape and realize value.
Across our experience and survey insights, a consistent pattern emerges. Boards tend to be most active at formal approval moments, while the decisions that actually determine long-term value happen earlier—during strategy, diligence, and operating model design—and later, during sustained integration. M&A leaders can help close that gap by reframing how and when boards engage.
Boards that evolve from milestone oversight to enterprise stewardship of transformation—aligned to long-term value creation rather than deal mechanics—are better positioned to drive successful global growth. M&A leaders who actively shape that engagement play a critical role in making that evolution possible.
In cross-border M&A, slow decision-making is often explained as a cultural issue. In reality, it is more often the result of decision-making architecture that was never explicitly recalibrated in light of the transaction.
Leaders frequently point to post-close frustrations—opaque approvals, repeated escalations, and revisited decisions—as evidence of integration challenges or cultural mismatch. These dynamics are more accurately understood as the downstream effects of implicit assumptions about the ways decisions are made—both during the deal process and in the end-state organization.
For M&A leaders, the implication is clear: They must design decision-making explicitly across the full deal life cycle, not assume it.
At deal inception, leaders should:
These actions do not slow deals down. They reduce friction, protect leadership attention, and allow teams to focus on where they can actually create value.
Cross-border M&A failures are often described as integration problems. In reality, many of them are operating model failures that were locked in before the deal even closed. When integration teams encounter slow decisions, unclear authority, or persistent escalation loops, the root cause is usually not execution discipline or cultural resistance. It is more likely the absence of a clearly articulated operating model—one that defines how the combined organization will actually run, make decisions, and allocate control across geographies.
This friction is visible well before integration begins, reinforcing a central finding of this series: Many post-merger integration failures are rooted in pre-close ambiguity, not post-close execution missteps.
Experienced deal leaders tend to converge on three operating model questions they must answer before integration planning begins. These are not PMI tactics; they are structural design choices.
For M&A leaders, the lesson is not to integrate more quickly, but to design earlier and more deliberately.
Operating model clarity is not an integration deliverable. It is a pre-signing leadership responsibility, refined through sign-to-close. It requires explicit trade-offs about control, autonomy, and decision-making that may feel uncomfortable—but which can be far less costly than resolving them post-close.
Cross-border M&A deals rarely lose value because integration teams fail. They lose it because deal teams ask people to integrate into an operating model that was never clearly defined.
In Japan, as detailed by reports from Bloomberg and Reuters, outbound deal activity has accelerated sharply, supported by governance reform, increased private equity participation, and greater willingness to pursue complex carve-outs and take-private transactions. For Japanese organizations, particularly in life sciences, M&A has become a critical mechanism to access global markets, innovation, and talent, as articulated in Deloitte’s “Beyond borders” publication.
Yet despite these trends, along with experience and capital, executives continue to report uneven value realization related to cross-border M&A. They are seeing missed synergies, slower integration, and momentum loss after close. To understand why, we surveyed 126 global life sciences executives who have direct experience in cross-border M&A involving Japanese and non-Japanese organizations. We also interviewed a dozen more in the US, Europe, and Asia Pacific. The results point to a clear conclusion: Organizations broadly agree on what makes cross-border M&A difficult, but they diverge sharply on the reasons deals struggle and where in the process they are actually losing value.
Endnotes:
*Throughout this article, figures reflect multi-select survey responses; percentages indicate frequency of selection rather than relative importance and are best interpreted directionally and comparatively across segments.